New Zealand markets closed

Novartis AG (NVS)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
101.14-0.95 (-0.93%)
At close: 04:00PM EDT
102.48 +1.34 (+1.32%)
After hours: 07:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close102.09
Bid100.00 x 800
Ask102.43 x 800
Day's range101.03 - 101.77
52-week range74.09 - 105.61
Avg. volume1,339,001
Market cap209.184B
Beta (5Y monthly)0.46
PE ratio (TTM)28.09
Earnings dateN/A
Forward dividend & yield3.50 (3.38%)
Ex-dividend date09 Mar 2023
1y target estN/A
  • GlobeNewswire

    Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab

    Positive CHMP opinion based on comprehensive package of analytical, pre-clinical and clinical dataBreast and gastric cancers are among most common types of cancer, accounting together for nearly half a million new cases every year in Europe alone1,2Sandoz is committed to accelerating access to potentially life-changing treatments and continues to strengthen its oncology and supportive care portfolioBasel, September 18, 2023 — Sandoz, a global leader in generic and biosimilar medicines, today ann

  • GlobeNewswire

    Novartis shareholders approve the proposed 100% Spin-off of Sandoz

    Shareholders approve the proposed 100% Spin-off of Sandoz, the Generics and Biosimilars business of NovartisShareholders also approve a reduction of share capital in connection with the Spin-off Novartis shareholders and Novartis ADR holders will receive one Sandoz share for every five Novartis shares or one Sandoz ADR for every five Novartis ADRs through the distribution of a dividend-in-kindThe Spin-off is planned to occur on or around October 4, 2023 Basel, September 15, 2023 — At an Extraord

  • GlobeNewswire

    Sandoz announces exclusive deal to commercialize biosimilar ustekinumab, further reinforcing growing pipeline and immunology patient offering

    Agreement with Samsung Bioepis gives Sandoz exclusive commercialization rights to biosimilar SB17 ustekinumab in Europe and North AmericaUstekinumab is a fully human monoclonal antibody to interleukin (IL)-12/23, approved for treatment of plaque psoriasis, psoriatic arthritis, Crohn´s disease and ulcerative colitis Deal further strengthens Sandoz position in immunology and supports further pipeline expansion Basel, September 11, 2023 — Sandoz, a global leader in generic and biosimilar medicines,